Physician profile
Sara E Pratt
NPI 1144208323
$1,162.29
in general payments reported to CMS, 2019-2025
18 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $24.30 · 2023: $163 · 2024: $208 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.32 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $196.76 | 2025 | Brukinsa |
| Astellas Pharma US INC | $116.80 | 2021-2024 | |
| Adc Therapeutics America, INC. | $104.24 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Janssen Biotech, INC. | $99.47 | 2025 | Carvykti, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $84.58 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $83.79 | 2021-2025 | Enhertu |
| Abbvie INC. | $71.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.20 | 2021-2025 | Reblozyl, Welireg, Keytruda |
| Beigene USA, INC. | $47.53 | 2023 | Brukinsa |
| Glaxosmithkline, LLC. | $46.25 | 2024 | Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $26.62 | 2021 | |
| Incyte Corporation | $24.30 | 2022 | |
| Kite Pharma, INC. | $22.77 | 2021 | |
| Seagen INC. | $22.70 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.20 | 2024 | Trodelvy |
| Eisai INC. | $19.01 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.96 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.